DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)

被引：0
|
作者：
Park, S. H. [1 ]
Castellano, D. [2 ]
Petrylak, D. P. [3 ]
Galsky, M. D. [4 ]
van der Heijden, M. S. [5 ]
Loriot, Y. [6 ]
Ogawa, O. [7 ]
Su, W-P. [8 ]
Huang, W. [9 ]
Levin, W. [9 ]
Ferro, S. [9 ]
Ben, Y. [9 ]
Bellmunt, J. [10 ]
Powles, T. [11 ]
机构：
[1] Samsung Med Ctr, Dept Med, Seoul, South Korea
[2] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[3] Yale Univ, Dept Med, New Haven, CT 06520 USA
[4] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[5] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[6] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[7] Kyoto Univ, Dept Urol, Kyoto, Japan
[8] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[9] AstraZeneca, Global Med Dev, Gaithersburg, MD USA
[10] Harvard Med Sch, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA
[11] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med Ctr, London, England
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
285TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).
    De Santis, Maria
    Wiechno, Pawel J.
    Lucas, Christel
    Su, Wu-Chou
    Albiges, Laurence
    Lin, Chia-Chi
    Bellmunt, Joaquim
    Senkus-Konefka, Elzbieta
    Flechon, Aude
    Mourey, Loic
    Necchi, Andrea
    Loidl, Wolfgang C.
    Morand, Maryse
    Burillon, Jean-Philippe
    Fougeray, Ronan
    Culine, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)
    Finn, R. S.
    Kudo, M.
    Cheng, A-L.
    Wyrwicz, L.
    Ngan, R.
    Blanc, J-F.
    Baron, A. D.
    Vogel, A.
    Ikeda, M.
    Piscaglia, F.
    Han, K-H.
    Qin, S.
    Minoshima, Y.
    Funahashi, Y.
    Ren, M.
    Dairiki, R.
    Sachdev, P.
    Tamai, T.
    Dutcus, C.
    Evans, T. R. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression
    Quinn, David I.
    Petrylak, Daniel Peter
    Bellmunt, Joaquim
    Necchi, Andrea
    Gurney, Howard
    Lee, Jae-Lyun
    Van Der Heijden, Michiel Simon
    Rosenbaum, Eli
    Penel, Nicolas
    Pang, See-Tong
    Li, Jian-Ri
    del Muro, Xavier Garcia
    Joly, Florence
    Papai, Zsuzsanna
    Ellinghaus, Peter
    Lu, Chengxing
    Nakajima, Keiko
    Ishida, Tatiane
    Nishiyama, Hiroyuki
    Sternberg, Cora N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [44] First-line Treatment of untreated, non-resectable or metastatic Urothelial Carcinoma: An open, randomized, Phase III Study of Nivolumab in Combination with Ipilimumab or Standard Chemotherapy versus Standard-Chemotherapy in Patients with previously untreated inoperable or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO
    Rexer, H.
    Retz, M.
    Waller, C.
    AKTUELLE UROLOGIE, 2019, 50 (01) : 20 - 21
  • [45] An open-label, randomized, Phase III Study of Nivolumab in Combination with Ipilimumab or with Standard Chemotherapy versus Standard Chemotherapy in Patients with previously untreated inoperable or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO First-line Therapy for untreated, non-resectable or metastatic Urothelial Carcinoma
    Rexer, H.
    Retz, M.
    Waller, C.
    UROLOGE, 2018, 57 (07): : 880 - 881
  • [46] Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study
    Buikhuisen, Wieneke A.
    Burgers, Jacobus A.
    Vincent, Andrew D.
    Korse, Catharina M.
    van Klaveren, Rob J.
    Schramel, Franz M. N. H.
    Pavlakis, Nick
    Nowak, Anna K.
    Custers, Frank L. J.
    Schouwink, J. Hugo
    Gans, Steven J. M.
    Groen, Harry J. M.
    Strankinga, Wim F. M.
    Baas, Paul
    LANCET ONCOLOGY, 2013, 14 (06): : 543 - 551
  • [47] Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy
    Shah, Amishi Yogesh
    Gao, Jianjun
    Rezazadeh, Arash
    Cole, Suzanne
    Jain, Rohit K.
    Stevenson, Alex
    Fyvie, Gayle
    Gaw, Nina Jane
    Pant, Shubham
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
    Lenz, Heinz-Josef
    Lee, Fa-Chyi
    Yau, Linda
    Koh, Han A.
    Knost, James A.
    Mitchell, Edith P.
    Bosanac, Ivan
    Mancao, Christoph
    Parikh, Aparna
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [49] A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
    Liu, Qing
    Lou, Yanni
    Li, Liya
    Yang, Guowang
    Cui, Huijuan
    Cheng, Zhiqiang
    Li, Yuan
    Liu, Meng
    Deng, Chao
    Wan, Donggui
    Yan, Yongxia
    Jia, Liqun
    INTEGRATIVE CANCER THERAPIES, 2022, 21
  • [50] A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
    Liu, Qing
    Lou, Yanni
    Li, Liya
    Yang, Guowang
    Cui, Huijuan
    Cheng, Zhiqiang
    Li, Yuan
    Liu, Meng
    Deng, Chao
    Wan, Donggui
    Yan, Yongxia
    Jia, Liqun
    INTEGRATIVE CANCER THERAPIES, 2022, 21
12345